{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:29:26Z","timestamp":1785288566680,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81904080"],"award-info":[{"award-number":["81904080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Chronic hepatitis B is often complicated with different degrees of hepatic fibrosis, which affects the quality of life. Nucleoside analogs are recommended by almost all guidelines in the world for the treatment of chronic hepatitis B. At present, there is no specific and effective chemical and biological agents for hepatic fibrosis. In China, Chinese compound prescription combined with nucleoside analogs have been used to treat hepatic fibrosis of chronic hepatitis B patients in more and more cases, and good results have been achieved. Several Chinese compound prescriptions that have been made into proprietary Chinese medicine for the convenience of use. This article aims to systematically evaluate the efficacy and safety of Chinese medicine compounds assisting nucleoside analogs in the treatment of hepatic fibrosis in chronic hepatitis B patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>The following databases will be searched from their inception to September 2019: PubMed, EMBASE, EBSCOhost, The Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical literature Database (CBM), VIP Database, Wanfang Database. Languages are limited to Chinese and English. The study includes randomized controlled trials using Chinese compound prescription combined with entecavir and Chinese compound prescription combined with tenofovir disoproxil fumarate to treat hepatic fibrosis of chronic hepatitis B patients. The primary outcomes including effective rate and biochemical parameters (levels of hyaluronic acid, laminin, pre-type-III collagen and type IV collagen will be tested. Additional outcomes include liver function indexes (levels of alanine aminotransferase, aspartate aminotransferase, total bilirubin) and levels of hepatitis B virus DNA. Stata14.0 software will be used for meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result:<\/jats:title>\n            <jats:p>The efficacy and safety of Chinese compound prescriptions assisting nucleoside analogs for hepatic fibrosis of chronic hepatitis B patients will be assessed from the effective rate, biochemical parameters, liver function indexes, and levels of hepatitis B virus DNA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The conclusion of this study will be used to evaluate the efficacy and safety of Chinese compound prescriptions assisting nucleoside analogs in the treatment of hepatic fibrosis of chronic hepatitis B patients, as well as the adjuvant effectiveness of Chinese compound prescriptions in combined therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration number:<\/jats:title>\n            <jats:p>CRD42020156859.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021032","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T16:39:35Z","timestamp":1593448775000},"page":"e21032","source":"Crossref","is-referenced-by-count":6,"title":["Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Maoyuan","family":"Cheng","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianrong","family":"Feng","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojia","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"(1 Suppl)","key":"R1-20240214","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J Hepatol"},{"key":"R2-20240214","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"R3-20240214","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jhep.2013.05.007","article-title":"Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy","volume":"59","author":"Liaw","year":"2013","journal-title":"J Hepatol"},{"key":"R4-20240214","first-page":"703","article-title":"Progress in treatment of liver fibrosis with traditional Chinese medicine [in Chinses]","volume":"27","author":"Xie","year":"2016","journal-title":"Lishizhen Med Mater Med Res"},{"key":"R5-20240214","first-page":"242","article-title":"Research progress in the mechanism of anti-fibrosis effect of traditional Chinese medicine and its compound [in Chinses]","volume":"26","author":"LV","year":"2020","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"R6-20240214","first-page":"74","article-title":"The therapy of entecavir combined with Anluo Huaxian capsule on HBeAg positive chronic hepatitis B-related liver fibrosis in 134 cases[in Chinses]","volume":"26","author":"Huang","year":"2016","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"key":"R7-20240214","first-page":"145","article-title":"Clinical observation of Bushen Rougan recipe in the treatment of liver fibrosis after hepatitis B [in Chinses]","volume":"25","author":"Zhang","year":"2015","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"key":"R9-20240214","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R10-20240214","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R11-20240214","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3122\/jabfm.2015.06.140331","article-title":"Management of chronic hepatitis B: an overview of practice guidelines for primary care providers","volume":"28","author":"Han","year":"2015","journal-title":"J Am Board Fam Med"},{"key":"R12-20240214","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R14-20240214","first-page":"2648","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2019) [in Chinses]","volume":"12","year":"2019","journal-title":"J Clin Hepatol"},{"key":"R15-20240214","first-page":"2163","article-title":"Consensus on the diagnosis and therapy of hepatic fibrosis (2019) [in Chinses]","volume":"35","year":"2019","journal-title":"J Clin Hepatol"},{"key":"R16-20240214","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.zefq.2012.06.013","article-title":"GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect)","volume":"106","author":"Meerpohl","year":"2012","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"R17-20240214","first-page":"1762","article-title":"Meta analysis of the effect of compound Biejiaruangan tablet combined with entecavir on serum markers of liver fibrosis in patients with chronic hepatitis B [in Chinses]","volume":"35","author":"Duan","year":"2015","journal-title":"Chin Hosp Pharm J"},{"key":"R18-20240214","first-page":"177","article-title":"Curative effect and quality of life of chronic hepatitis B patients with liver fibrosis with syndromes of liver depression, spleen deficiency and blood stasis obstruction treated with ruangan huaxian decoction combined with entecavir [in Chinses]","volume":"23","author":"Zeng","year":"2017","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"R19-20240214","first-page":"3817","article-title":"Effects of compound danshen dripping pills or tablets on chronic hepatitis B complicated with hepatic fibrosis: a systematic review [in Chinses]","volume":"28","author":"Zhang","year":"2017","journal-title":"China Pharmacy"},{"key":"R20-20240214","first-page":"133","article-title":"Clinical effect of entecavir combined with DahuangZhechong pills in the treatment of hepatitis B liver fibrosis [in Chinses]","volume":"3","author":"Chen","year":"2018","journal-title":"Clin Res Pract"},{"key":"R21-20240214","first-page":"1031","article-title":"Systematic evaluation of compound Biejia Ruangan tablets combined with entecavir in the treatment of chronic hepatitis B complicated with hepatic fibrosis [in Chinses]","volume":"19","author":"Liao","year":"2019","journal-title":"Eval Anal Drug Use Hosp China"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:08:36Z","timestamp":1707926916000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021032"}},"subtitle":["A protocol of systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":19,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021032","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}